Compare Globus Medical Inc. Class A Common Stock (GMED) vs L3Harris Technologies Inc (LHX) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

LHX trades at $234.72, down 1.48% today, amid a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent contract wins totaling over $10 billion for THAAD and PAC-3 MSE propulsion systems highlight growth potential, though multiple law firm investigations create investor uncertainty. Revenue has grown steadily from $17.1B in 2022 to $21.9B in 2025, with profit margins improving to 7.34%.

Analysts remain bullish with a $340 consensus price target (45% upside), but technical indicators show selling pressure. Key risks include ongoing legal investigations and execution challenges on major defense contracts. The stock offers value with a P/E of 23.71 below industry averages, supported by strong cash flow generation and dividend payments.